GT Biopharma, Inc.GTBPNASDAQ
Loading
| Metric | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 |
|---|---|---|---|---|---|
| Revenue Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| Gross Profit Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| EBITDA Growth | +0.00% | -194.06% | +0.00% | +0.00% | +0.00% |
| Operating Income Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| Net Income Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| EPS Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| EPS Diluted Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| Weighted Average Shares Growth | +37.36% | +69.80% | +61.90% | +76.40% | +190.63% |
| Weighted Average Shares Diluted Growth | +37.36% | +69.80% | +61.90% | +76.40% | +190.63% |
| Dividends per Share Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| Operating Cash Flow Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| Free Cash Flow Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| Receivables Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| Inventory Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| Asset Growth | -70.00% | -73.18% | -23.13% | -36.07% | +91.54% |
| Book Value per Share Growth | +0.00% | +0.00% | -45.98% | -18.90% | +0.00% |
| Debt Growth | -100.00% | -100.00% | +0.00% | +0.00% | +0.00% |
| R&D Expense Growth | +42.23% | +41.44% | -79.65% | -51.49% | -28.70% |
| SG&A Expenses Growth | +1.21% | -64.00% | -45.81% | +19.63% | +130.17% |